Overview

Efficacy and Safety of Lansoprazole on Gastric and Duodenal Ulcers in Patients Taking Nonsteroidal Anti-Inflammatory Drugs

Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether AG-1749 (lansoprazole), once daily (QD), is effective in preventing the recurrence of gastric and duodenal ulcers in patients receiving long term treatment with nonsteroid anti-inflammatory drug, compared to gefarnate, twice daily (BID).
Phase:
Phase 3
Details
Lead Sponsor:
Takeda
Treatments:
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Dexlansoprazole
Gefarnate
Lansoprazole